Digital Tracking to Monitor Activity of Inflammatory Bowel Disease
Studies wearable data and patient reports in adults with Crohn disease or ulcerative colitis.
Plain-language title generated from the registry record
Registry title: Multiple Digital Biomarkers for Optimization of IBD Care
Key facts
- Where
- Bonheiden, BelgiumSee the site
Where in Belgium
- Imelda General HospitalBonheiden, BelgiumNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Imelda GI Clinical Research Center
- Trial code
- NCT07159776
- Record updated
- 8 September 2025
- Original description
To develop digital biomarkers associated with disease activity of inflammatory bowel diseaseRead full original descriptionShow less
Multiple Digital Biomarkers for Optimization of IBD Care
To develop digital biomarkers associated with disease activity of inflammatory bowel disease
Inclusion: Males or females aged > 18 years; Diagnosis of CD, UC or IBD-unspecified for at least 1 month; Treatment with conventional or advanced therapy for IBD at initiation of the study; The patient must have access to an email address; The patient must be willing to perform all the groceries shopping at any of the Colruyt Group stores during this study, using an Xtra card created by the study team; Capacity to independently answer regular digital questionnaires; Capacity and willingness to use a smartphone and activity tracker.
Exclusion: Previous colectomy; Significant medical condition interfering with physiological measurements trough a wearable device (heart failure, pacemaker or defibrillator); Planned extended (> 1 month) overseas travel during the study period of 12 months, if internet access would be impossible, inconvenient or unaffordable during this time; Inability to communicate well with investigators or unable to comply with the study requirements; Inclusion or planned inclusion in an interventional IBD-related clinical trial.